Form 4: Myomo CEO Receives RSU Grant

Myomo, Inc. CEO Paul R. Gudonis received a grant of 19,395 Restricted Stock Units (RSUs) valued at 115% of foregone salary.

Summary

• Paul R. Gudonis, CEO and Director of Myomo, Inc., was granted 19,395 Restricted Stock Units (RSUs) on April 10, 2026.
• This grant is part of a program where employees can elect to receive RSUs in lieu of 10% of their salary.
• The RSUs granted have a fair value of 115% of the foregone salary.
• The grant covers the exchange of three months of salary.
• All RSUs granted will vest in their entirety on July 9, 2026.
• Following this transaction, Mr. Gudonis beneficially owns 1,280,045 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard executive compensation transaction (RSU grant) without providing new financial or strategic information.

Positives

• The CEO is participating in a compensation program that aligns his interests with shareholders through equity grants.
• The RSU grant is valued at a premium (115%) to the foregone salary, indicating a favorable exchange for the employee.
• The CEO's continued beneficial ownership of a significant number of shares (1,280,045) suggests a long-term commitment to the company.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the RSUs is subject to market fluctuations and the company's stock performance.
• Vesting is contingent on continued employment until July 9, 2026.

Future Outlook

The filing does not contain forward-looking statements or guidance. The vesting date of July 9, 2026, for the RSUs is a future event.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as Restricted Stock Units (RSUs), is a common practice in the biotechnology and medical device sectors to attract and retain key talent, particularly executives. The structure of this grant, allowing employees to defer salary for RSUs at a premium, is a strategic compensation tool often employed to manage cash flow while incentivizing long-term performance.

Comparison to Industry Standards

• The practice of granting RSUs in lieu of salary is a recognized executive compensation strategy within the technology and healthcare sectors.
• Companies often use RSU grants to align executive interests with shareholder value, with vesting periods typically ranging from one to four years.
• Valuing these grants at a premium to the foregone salary is a less common but acceptable incentive mechanism, aiming to provide an enhanced reward for deferred compensation.

Related Party Transactions

• The grant of RSUs to CEO Paul R. Gudonis in exchange for foregone salary is a related party transaction, as it involves compensation for a key executive.

Stakeholder Impact

• Shareholders: The RSU grant represents a form of compensation that dilutes ownership slightly upon vesting, but it also aligns executive incentives with long-term company performance.
• Employees: The program allows employees to participate in the company's potential future stock appreciation.
• Management: The CEO receives additional equity compensation, reinforcing his commitment to the company.

Next Steps

• The RSUs will vest on July 9, 2026.
• The company's performance and stock price will determine the ultimate value of the RSUs.

Key Dates

Keywords

Myomo Inc, MYO, Form 4, Restricted Stock Units, RSU, Stock Grant, Executive Compensation, Insider Trading, Beneficial Ownership, Paul R. Gudonis